ICD-10 Code D02.20. ICD D02.20 is a billable code used to specify a medical diagnosis of carcinoma in situ of unspecified bronchus and lung. The code is valid for the year 2019 for the submission of HIPAA-covered transactions.
One study found that depending on the stage of the metastases (spread) the average survival time following diagnosis of metastatic lung cancer ranged from 6.3 months to 11.4 months. There are a number of factors that can impact life expectancy with metastatic lung cancer. Factors associated with a less favorable outcome include:
Malignant neoplasm of ectopic tissue
ICD-10 Code for Secondary malignant neoplasm of unspecified site- C79. 9- Codify by AAPC.
C34. 90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung | ICD-10-CM.
C80. 1 - Malignant (primary) neoplasm, unspecified | ICD-10-CM.
51, C80. 1. If the documentation states the cancer is a metastatic cancer, but does not state the site of the metastasis, the coder will assign a code for the primary cancer, followed by code C79. 9 secondary malignant neoplasm of unspecified site.
ICD-10 code C34. 90 for Malignant neoplasm of unspecified part of unspecified bronchus or lung is a medical classification as listed by WHO under the range - Malignant neoplasms .
For example, lung mass and multiple lung nodules are specifically indexed to code R91. 8, Other nonspecific abnormal finding of lung field.
Disseminated malignant neoplasm, unspecified C80. 0 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM C80. 0 became effective on October 1, 2021.
Not all cancers are carcinoma. Other types of cancer that aren't carcinomas invade the body in different ways. Those cancers begin in other types of tissue, such as: Bone.
Metastatic adenocarcinoma is a cancer that originates in glandular cells (mucus-secreting cells) such as milk ducts, the digestive tract, or lungs, and has spread or metastasized beyond the tissue in which it began.
Metastatic cancer has the same name as the primary cancer. For example, breast cancer that spreads to the lung is called metastatic breast cancer, not lung cancer. It is treated as stage IV breast cancer, not as lung cancer.
1 Malignant (primary) neoplasm, unspecified and C79. 9 Secondary malignant neoplasm of unspecified site. A diagnosis of metastatic cancer not otherwise specified (NOS) is used most often when diagnostic tests were not completed.
Cancer of the lung, squamous cell, stage 1. Cancer of the lung, squamous cell, stage 2. Cancer of the lung, squamous cell, stage 3. Cancer of the lung, squamous cell, stage 4. Cancer, lung, non small cell. Eaton-lambert syndrome due to small cell carcinoma of lung. Eaton-lambert syndrome due to small cell lung cancer.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
Cancer that forms in tissues of the lung, usually in the cells lining air passages. The two main types are small cell lung cancer and non-small cell lung cancer. These types are diagnosed based on how the cells look under a microscope.
The 2022 edition of ICD-10-CM C34.90 became effective on October 1, 2021.
In most cases the manifestation codes will have in the code title, "in diseases classified elsewhere.". Codes with this title are a component of the etiology/manifestation convention. The code title indicates that it is a manifestation code.
C34 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail. The 2021 edition of ICD-10-CM C34 became effective on October 1, 2020. This is the American ICD-10-CM version of C34 - other international versions of ICD-10 C34 may differ. Use Additional.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
The 2022 edition of ICD-10-CM C78.00 became effective on October 1, 2021.
Malignant neoplasm of main bronchus 1 C34.0 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail. 2 The 2021 edition of ICD-10-CM C34.0 became effective on October 1, 2020. 3 This is the American ICD-10-CM version of C34.0 - other international versions of ICD-10 C34.0 may differ.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
The 2022 edition of ICD-10-CM C34.0 became effective on October 1, 2021.
*Note: Cancer registries throughout the world do not use the /6 behavior code (metastatic). Registries report the behavior of the primary tumor, not the metastic tumor. The /6 is used infrequently by pathologists in very few places in the world.
The ICD-10 alphabetic index (Vol.3) contains, under the term "neoplasm," a table of five columns with the following headings: Malignant, Secondary or Metastatic, In situ, Benign, Uncertain and Unknown Behavior. Appropriate ICD-10 categories for each site of the body are then listed in alphabetic order. Figure 2 shows the entry for lung neoplasms.